BIOTA HOLDINGS LIMITED

ASX:BTA ISIN:AU000000BTA1

2012年2月10日

概覽 | 新聞 | 多媒體 | 研究

BIOTA HOLDINGS LIMITED 公司資料

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU influenza diagnostics. Relenza(tm) is a registered trademark of the GlaxoSmithKline group of companies. BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical. *Further information available at www.biota.com.au.

公司詳細

	總部	Unit 10, 585 Blackburn Road

		NOTTING HILL VIC 3168

		Australia

	電話	+61 3 9915 3700

	傳真	+61 3 9915 3702

	主要部門	醫療-製藥

	支柱產業	生物科技

	主頁	www.biota.com.au

Key Developments: BIOTA HOLDINGS LIMITED

	8月13日澳洲股市：美國經濟趨穩 AUG 13, 2009 11:03 - Article Views: 8,745 因美聯儲表示經濟正在回穩，而且在為期兩天的政策會議結束時保持利率不變，美國股市昨晚飆升。

	3月30日澳洲股市：數週暴漲之後放緩 MAR 30, 2009 13:00 - Article Views: 7,259 澳洲股市在礦業股的抬升下收市微漲。當日基本指數S&P/ASX200收盤上漲0.7%，或25.7點，報3672.3點。綜合指數上漲0.8%，或29.3點，報3615.6點。 ASX200一周上漲幅度為6%，綜合指數一周漲幅為6.2%。

	1月30日澳洲市場：連續三天的大漲告一段落 JAN 30, 2009 13:00 - Article Views: 8,373 週四澳洲股市在海外市場漲勢以及商品價格走強的帶動下連續第三天上漲。基本指數S&P/ASX200上漲30.7點，或0.88%，報3526.2點；綜合指數上升26.2點，或0.76%，報3461.3點。在華爾街大跌之後，澳洲股市可能會失掉近期的收益。